Frederick B Stehman
Affiliation: Indiana University
- Carcinoma of the vulvaFrederick B Stehman
Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
Obstet Gynecol 107:719-33. 2006..Adequately powered trials aimed at further reducing morbidity without compromising survival are underway...
- Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyFrederick B Stehman
Indiana University School of Medicine, Indianapolis, IN 46202, USA
Gynecol Oncol 127:495-501. 2012..We assessed whether G-CSF or ESA were associated with progression or death in patients with ovarian cancer...
- Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trialFrederick B Stehman
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Am J Obstet Gynecol 197:503.e1-6. 2007....
- Node count and groin recurrence in early vulvar cancer: A Gynecologic Oncology Group studyFrederick B Stehman
Gynecologic Oncology, The Clarence E Ehrlich Chair Emeritus, Department of Obstetrics and Gynecology, Indiana University School of Medicine, 535 Barnhill, 433, Indianapolis, IN 46202, USA
Gynecol Oncol 113:52-6. 2009..To determine if low node count from superficial groin dissection correlated with first recurrence in the groin for patients with early vulvar cancer...
- Innovations in the treatment of invasive cervical cancerFrederick B Stehman
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5274, USA
Cancer 98:2052-63. 2003..Research advances in both diagnosis and treatment are expected to improve therapy and outcomes...
- Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group studyPeter G Rose
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Gynecol Oncol 121:542-5. 2011..To evaluate the outcome of stage IVA cervical cancer treated with radiation and concurrent cisplatin-based chemotherapy...
- Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized TPeter G Rose
Peter G Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY Charles W Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE Frederick B Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA Gillian M Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada and Paul A DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI
J Clin Oncol 33:2136-42. 2015..To evaluate the prognostic factors in locally advanced cervical cancer limited to the pelvis and develop nomograms for 2-year progression-free survival (PFS), 5-year overall survival (OS), and pelvic recurrence...
- Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiationPeter G Rose
Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH 44195, United States Electronic address
Gynecol Oncol 135:208-12. 2014..The current study sought to evaluate impact of adeno- and adenosquamous histology in the randomized trials of primary cisplatin-based chemoradiation for locally advanced cervical cancer...
- Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapyJeanne M Schilder
Department of Ob Gyn, Division of Gynecologic Oncology, Indiana University Medical Center, 535 Barnhill Drive, Rm 436, Indianapolis, IN 46202 6294, USA
Gynecol Oncol 87:1-7. 2002..The purpose of this study was to determine the recurrence rate, survival, and pregnancy outcome in patients with Stage IA and Stage IC invasive epithelial ovarian cancer treated with unilateral adnexectomy...
- Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancerLisa M Hess
Indiana University School of Medicine, Department of Obstetrics and Gynecology, Indianapolis, IN 46202, USA
Gynecol Oncol 127:564-8. 2012..The goal of this study was to describe the various pathways and to identify an optimal path to accurate diagnosis...
- State of the science in ovarian cancer quality of life research: a systematic reviewLisa M Hess
Department of Public Health, Indiana University School of Medicine, Indianapolis 46202, USA
Int J Gynecol Cancer 22:1273-80. 2012..Quality-of-life outcomes are important in ovarian cancer, which has not yet benefitted from improved survival outcomes as have other diseases. This study was designed to systematically assess and summarize HRQOL in ovarian cancer...
- Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancerQingchun Cai
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
FASEB J 26:3306-20. 2012..PLA(2) activity was found in conditioned media from both EOC cells and macrophages. Collectively, our work implies that PLA(2) activity is a potential marker and therapeutic target in EOC...
- Stage Ia-IIa cancer of the cervixJeanne M Schilder
Indiana University School of Medicine, 535 Barnhill Drive, Room 436, Indianapolis, IN 46202 5274, USA
Cancer J 9:395-403. 2003..A thorough discussion between the physician and patient is necessary to determine the optimal management for each individual. This review discusses the major factors that influence physician and patient management choices...
- "What's in a name? That which we call a rose, by any other name."Frederick B Stehman
Obstet Gynecol 100:1146-7. 2002
- Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology GroupHenry M Keys
Department of Radiation Oncology, Albany Medical College, Albany, NY 12208, USA
Gynecol Oncol 89:343-53. 2003..To evaluate, in a randomized clinical trial, the role of adjuvant hysterectomy after standardized radiation in improving progression-free survival and survival for patients with "bulky" stage IB cervical cancer...
- Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology GroupMahesh A Varia
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
J Clin Oncol 21:2849-55. 2003....
- A thousand several tonguesFrederick B Stehman
Gynecol Oncol 94:247-8. 2004